stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Revenue growth
10x Genomics's revenue growth over the twelve months to 30 September 2026 was −3.62%, down 8.9 percentage points from fiscal 2025 (5.25%). Over the past ten years it has ranged from −51.4% (fiscal 2017) to 105.8% (fiscal 2018); the current reading is higher than 33% of that period. That is below the Medical Devices industry median of 10.4% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 5.25% | 6.53 |
| FY2024 | −1.28% | (21.09) |
| FY2023 | 19.8% | 14.53 |
| FY2022 | 5.28% | (58.85) |
| FY2021 | 64.1% | 42.60 |
| FY2020 | 21.5% | (46.53) |
| FY2019 | 68.1% | (37.77) |
| FY2018 | 105.8% | 157.25 |
| FY2017 | −51.4% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 1.12% | 13.77 |
| Jun 2026 | −12.7% | (10.04) |
| Mar 2026 | −2.61% | (3.22) |
| Dec 2025 | 0.61% | 2.36 |
| 27 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| PODD Insulet Corporation compare | 26.5% |
| PEN Penumbra, Inc. compare | 17.0% |
| GMED Globus Medical, Inc. compare | 13.4% |
| SNN Smith & Nephew SNATS, Inc. compare | 4.81% |
| HAE Haemonetics Corporation compare | 4.11% |
| BRKR Bruker Corporation compare | 2.16% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.38% |
| BIO Bio-Rad Laboratories, Inc. compare | 1.38% |
| TXG 10x Genomics | −4.28% |
| Medical Devices industry median | 10.4% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement